PIERIS PHARMACEUTICALS INC
COM · CUSIP 720795103
1
institutional holders
-41 vs Q1 2024
14.0k
shares reported held*
$2.4kreported value*
0 new
0 added
0 reduced
40 sold out
net sold ≈ $6.5m (-37.7m shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $0.17.
Trends to Q2 2024
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 65 |
| Q4 2022 | 64 |
| Q1 2023 | 61 |
| Q2 2023 | 50 |
| Q3 2023 | 45 |
| Q4 2023 | 47 |
| Q1 2024 | 42 |
| Q2 2024 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 21 | 30 |
| Q1 2023 | 18 | 29 |
| Q2 2023 | 14 | 34 |
| Q3 2023 | 17 | 17 |
| Q4 2023 | 14 | 15 |
| Q1 2024 | 16 | 15 |
| Q2 2024 | 0 | 40 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
CallsPuts
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q3 2023 | $23.6k | $1.3k | 0.05 |
| Q4 2023 | $14.0k | $783 | 0.06 |
| Q1 2024 | $0 | $37 | — |
| Q2 2024 | $0 | $0 | — |
Biggest buyers
| None |
Biggest sellers
| BVF INC/IL | Sold out | -20.6m |
| Lynx1 Capital Management LP | Sold out | -8.8m |
| RENAISSANCE TECHNOLOGIES LLC | Sold out | -1.4m |
| BlackRock Inc. | Sold out | -1.0m |
| CITADEL ADVISORS LLC | Sold out | -967.2k |
| ACADIAN ASSET MANAGEMENT LLC | Sold out | -962.4k |
| VANGUARD GROUP INC | Sold out | -907.4k |
| GEODE CAPITAL MANAGEMENT, LLC | Sold out | -772.8k |
| CM Management, LLC | Sold out | -575.0k |
| NORTHERN TRUST CORP | Sold out | -243.6k |
Holders, Q2 2024
| Manager | Shares | Change |
|---|---|---|
| Orange Investment Advisors, Inc. 0.00% of their portfolio | 14.0k $2.4k | Unchanged |